Clinical Trials Logo

Reflux Esophagitis clinical trials

View clinical trials related to Reflux Esophagitis.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06062225 Not yet recruiting - Clinical trials for Postoperative Complications

Protocol for Comparing the Efficacy of Three Reconstruction Methods of the Digestive Tract After Proximal Gastrectomy

Start date: October 2023
Phase: N/A
Study type: Interventional

The efficacy of three different reconstruction methods after proximal gastrectomy will be investigated in this study through a prospective, multicenter, randomized controlled trial.

NCT ID: NCT06056973 Not yet recruiting - Reflux Esophagitis Clinical Trials

Jinghua Weikang Capsule in the Treatment of Reflux Esophagitis

Start date: October 1, 2023
Phase: Phase 4
Study type: Interventional

Reflux esophagitis is a common clinical disease ; pPI or potassium competitive acid blocker ( P-CAB ) is the first choice for the treatment of reflux esophagitis. However, patients with recurrent symptoms and severe esophagitis ( Los Angeles grade C and D ) after long-term use of PPI or P-CAB usually need long-term maintenance treatment. Attention should be paid to the possible adverse reactions of long-term acid suppression therapy and the interaction between drugs. The main efficacy of Jinghua Weikang capsules is regulating qi and dispersing cold, clearing heat and removing blood stasis. Applicable to cold and heat syndrome, qi stagnation and blood stasis caused by epigastric distension, pain, belching, acid reflux, noisy, bitter taste ; duodenal ulcer see the above syndrome. In the early stage, a series of studies were carried out on Jinghua Weikang Capsule, which confirmed that Jinghua Weikang Capsule showed the effect of acid inhibition and symptom relief in the treatment of reflux esophagitis, and had a synergistic effect when combined with western medicine. However, Jinghua Weikang Capsule still lacks sufficient evidence to support the reduction of the recurrence rate of reflux esophagitis. Therefore, we carried out this experiment to explore the clinical efficacy of Jinghua Weikang Capsule in the maintenance treatment of reflux esophagitis, so as to reduce the recurrence rate of reflux esophagitis and relieve symptoms.

NCT ID: NCT05604261 Not yet recruiting - Clinical trials for Gastroesophageal Reflux

A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis

Start date: December 2022
Phase: Phase 2
Study type: Interventional

A phase 2, randomized, double-blind, double-dummy, positive drug parallel controlled, multicenter trial to evaluate efficacy and safety of within 8 weeks (including 8 weeks) treatment of Anaprazole 40mg QD, 60mg QD compared with Rabeprazole 20mg QD in patients with reflux esophagitis.

NCT ID: NCT01560598 Not yet recruiting - Reflux Esophagitis Clinical Trials

Adipokines and the Risk of Reflux Esophagitis

Start date: June 2012
Phase: N/A
Study type: Observational

We aimed to risk faoctors for GERD and association between visceral obesity, plasma adipoline(leptin, adiponectin, IL-6, TNF-α)and development of reflux esophagitis in healthy Koreans.